Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rajiv Raja

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
JAMA Oncology|April 10, 2020
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical TrialNaiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 2, 2014
Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefitHartmut Koeppen, Wei Yu, Jiping Zha, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
JAMA Oncology|April 10, 2020
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical TrialNaiyer A Rizvi, Byoung Chul Cho, Niels Reinmuth, et al.
Pageof 4